PlexinA1 promotes gastric cancer migration through preventing MICAL1 protein ubiquitin/proteasome-mediated degradation in a Rac1-dependent manner

Metastasis promotes the development of tumors and is a significant cause of gastric Cancer death. For metastasis to proceed, tumor cells must become mobile by modulating their Cytoskeleton. MICAL1 (Molecule Interacting with CasL1) is known as an actin Cytoskeleton regulator, but the mechanisms by which it drives gastric Cancer cell migration are still unclear. Analysis of gastric Cancer tissues revealed that MICAL1 expression is dramatically upregulated in stomach adenocarcinoma (STAD) samples as compared to noncancerous stomach tissues. Patients with high MICAL1 expression had shorter overall survival (OS), post-progression survival (PPS) and first-progression survival (FPS) compared with patients with low MICAL1 expression. RNAi-mediated silencing of MICAL1 inhibited the expression of Vimentin, a protein involved in epithelial-mesenchymal transition. This effect correlates with a significant reduction in gastric Cancer cell migration. MICAL1 overexpression reversed these preventive effects. Immunoprecipitation experiments and immunofluorescence assays revealed that PlexinA1 forms a complex with MICAL1. Importantly, specific inhibition of PlexinA1 blocked the Rac1 activation and ROS production, which, in turn, impaired MICAL1 protein stability by accelerating MICAL1 ubiquitin/proteasome-dependent degradation. Overexpression of PlexinA1 enhanced Rac1 activation, ROS production, MICAL1 and Vimentin expressions, and favored cell migration. In conclusion, this study identified MICAL1 as an important facilitator of gastric Cancer cell migration, at least in part, by affecting Vimentin expression and PlexinA1 promotes gastric Cancer cell migration by binding to and suppressing MICAL1 degradation in a Rac1/ROS-dependent manner.

Gastric cancer; MICAL1; Migration; PlexinA1; Rac1.